Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2022-11-07 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES POSTER PRESENTATION OF PHASE I, SINGLE-DOSE STUDY OF ASC43F FOR NASH AT AASLD ANNUAL MEETING 2022
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding a poster presentation of a Phase I clinical study at a scientific meeting (AASLD Annual Meeting 2022). It contains study design, pharmacokinetic results, and conclusions about the drug ASC43F. There is no indication that this is a formal financial report, regulatory filing, or management discussion. The document is relatively short (4348 characters) and is an announcement of scientific data rather than financial or corporate governance information. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a voluntary business update announcement related to clinical development progress, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-11-07 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks for World Houseware (Holdings) Limited. It includes detailed information about the exercise of share options, changes in the number of issued shares, and confirmations related to compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on equity issuance and share capital changes, with no financial statements or earnings data. This matches the description of a Share Issue/Capital Change announcement rather than a full financial report or other filing types. Therefore, the appropriate classification is 'SHA' (Share Issue/Capital Change). The document length and detail support a high confidence in this classification.
2022-11-04 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS'STRATEGIC PARTNER SAGIMET BIOSCIENCES ANNOUNCES POSITIVE INTERIM PHASE 2B CLINICAL TRIAL DATA WITH ASC40 (DENIFANSTAT), A FIRST-IN-CLASS FATTY ACID SYNTHASE INH
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding positive interim Phase 2b clinical trial data for a drug candidate (ASC40/Denifanstat). It includes detailed clinical trial results, statistical significance, and upcoming presentation information. There is no indication that this is a full financial report, audit, or regulatory filing. It is not a transcript, capital update, or management change announcement. The document is an announcement of clinical trial progress and data, which does not fit into financial or governance report categories. It is not a report publication announcement since it contains substantive data and details rather than just a notice of report availability. Given the content and context, this is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial results and business development, which does not fit other specific categories.
2022-11-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2022
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 October 2022. It details movements in authorized and issued shares, share options, and confirms no changes in warrants or convertibles. The document is submitted to the Hong Kong Exchanges and Clearing Limited and includes detailed tables on share capital and share options. It is a regulatory submission about share capital movements rather than a financial report, earnings release, or management discussion. It does not contain financial statements or management commentary. The document is a regulatory filing related to share capital movements and share options under exchange rules, fitting the category of Regulatory Filings (RNS) as it does not fit other more specific categories like Share Issue/Capital Change (SHA) because it reports no changes in issued shares or capital during the month, and it is a standard monthly return submission to the exchange.
2022-11-03 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. IND FILING OF ORAL 3CLPRO INHIBITOR ASC11 FOR COVID-19
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the filing of an Investigational New Drug (IND) application for a new oral drug candidate ASC11 targeting COVID-19. It is an announcement of a business development event related to drug development and regulatory filing to the FDA. The document is relatively short (3055 characters) and does not contain financial data, financial statements, or detailed report content. It is not a full financial report, earnings release, or management discussion. It is also not a regulatory certification or officer attestation. The content fits best as a general regulatory announcement about a significant corporate event, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2022-11-02 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 October 2022
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return regarding movements in securities, specifically focusing on authorized and issued shares, share options, and confirmations related to securities issued by the company. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with listing rules under the Stock Exchange of Hong Kong. The content is regulatory in nature, providing updates on share capital and share movements rather than financial performance or management commentary. It does not contain financial statements or earnings data, nor is it a report like an annual or interim report. It is also not a simple announcement or a certification letter but a formal regulatory submission detailing share capital movements. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2022-11-01 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.